Literature DB >> 8401536

Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE).

B Smith-Sørensen1, M C Gebhardt, P Kloen, J McIntyre, F Aguilar, P Cerutti, A L Børresen.   

Abstract

We have previously developed conditions to screen for TP53 point mutations inside the conserved domains II-V of the gene by using constant denaturant gel electrophoresis (CDGE). The present study reports conditions for screening more of the codons in the frequently mutated region exon 5-8 and for detecting mutations in sequences encoding functional domains in the N- and C-terminal part of the protein. The ability of the CDGE technique to detect mutations was studied using controls with known sequence deviations. The resolution power of the technique to separate different types of mutations was tested by using seven different single base pair mutants all residing in a stretch of four base pairs. All mutants were separated from the wild type. The established CDGE screening strategy was then used to look for mutations in DNA from 28 osteosarcomas. Six (21.5%) of the samples were shown to have a TP53 mutation, and the exact characterization was performed by direct sequencing. All of these were within the frequently reported mutated region exon 5-8.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8401536     DOI: 10.1002/humu.1380020407

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  7 in total

1.  Alterations of the p53, Rb and MDM2 genes in osteosarcoma.

Authors:  C W Miller; A Aslo; A Won; M Tan; B Lampkin; H P Koeffler
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 2.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

3.  Characterization of protistan assemblages in the Ross Sea, Antarctica, by denaturing gradient gel electrophoresis.

Authors:  Rebecca J Gast; Mark R Dennett; David A Caron
Journal:  Appl Environ Microbiol       Date:  2004-04       Impact factor: 4.792

4.  TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material.

Authors:  S Gretarsdottir; L Tryggvadottir; J G Jonasson; H Sigurdsson; K Olafsdottir; B A Agnarsson; H Ogmundsdottir; J E Eyfjörd
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

5.  Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families.

Authors:  M Zelada-Hedman; A L Børresen-Dale; A Claro; J Chen; L Skoog; A Lindblom
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo.

Authors:  P De Angelis; T Stokke; L Smedshammer; R A Lothe; G Lehne; Y Chen; O P Clausen
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

7.  Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.

Authors:  B Smith-Sørensen; J Kaern; R Holm; A Dørum; C Tropé; A L Børresen-Dale
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.